The same increase of cleaved PARP and p21 was also observed with the Hh inhibitors KAAD or ATO, whereas neither MGCD0103 nor Hh inhibitors affected p53 and Bcl-2 levels (Fig. 2g), indicating that these compounds limit tumor growth by modulating common targets. The gene discussed is TP53; the disease is neoplasm.